MALVERN, Pa., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of its previously announced registered direct offering for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of $1.50 per share (or pre-funded warrant in lieu thereof).

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The aggregate gross proceeds to the Company from the offering were approximately $6 million, before deducting the placement agent fees and other offering expenses payable by the Company. The Company currently intends to use the net proceeds from the offering toward working capital and general corporate purposes.

The securities described above were offered and sold by the Company pursuant to a "shelf" registration statement ...